A carregar...
Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
Immunoglobulin (Ig)-replacement therapy represents the mainstay of treatment for patients with primary antibody deficiency and is administered either intravenously (IVIg) or subcutaneously (SCIg). While hyaluronidase has been used in clinical practice for over 50 years, the development of a high-pur...
Na minha lista:
| Publicado no: | Immunotargets Ther |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4928364/ https://ncbi.nlm.nih.gov/pubmed/27471693 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S31136 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|